Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis
V Ranpura, S Hapani, S Wu - Jama, 2011 - jamanetwork.com
Context Fatal adverse events (FAEs) have been reported in cancer patients treated with the
widely used angiogenesis inhibitor bevacizumab in combination with chemotherapy.
Currently, the role of bevacizumab in treatment-related mortality is not clear. Objective To
perform a systematic review and meta-analysis of published randomized controlled trials
(RCTs) to determine the overall risk of FAEs associated with bevacizumab. Data Sources
PubMed, EMBASE, and Web of Science databases as well as abstracts presented at …
widely used angiogenesis inhibitor bevacizumab in combination with chemotherapy.
Currently, the role of bevacizumab in treatment-related mortality is not clear. Objective To
perform a systematic review and meta-analysis of published randomized controlled trials
(RCTs) to determine the overall risk of FAEs associated with bevacizumab. Data Sources
PubMed, EMBASE, and Web of Science databases as well as abstracts presented at …